20 June 2013
Keywords: emea, supports, abbott, synagis, use, pediatric, chd
Article | 04 August 2003
The European Medicines Evaluation Agency has granted a positive opinion for the use of Abbott Laboratories' Synagis (palivizumab) in young
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
4 August 2003
11 August 2003
19 June 2013
© 2013 thepharmaletter.com